GLP1R and type 2 diabetes mellitus: In recent years, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for the treatment of type 2 diabetes and obesity, have drawn increasing attention in the context of chronic inflammatory diseases (6, 7).